Presentations and e-publications from SCCA clinicians to feature the latest research on breast, gastrointestinal, genitourinary, lung, renal and sarcoma cancers, and hematological malignancies
SEATTLE–(BUSINESS WIRE)–Seattle Cancer Care Alliance (SCCA), announced today the new findings from its clinicians that will be featured at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program May 29-31, 2020.
SCCA clinicians contributed to discoveries from clinical trials across multiple cancer types, including results from immunotherapy clinical trials. They provided perspectives on the clinical impact of COVID-19 on patients with cancer and on financial issues associated with clinical trials and cancer treatment. They also contributed to new findings related to genetic testing, cardiovascular disease among women with breast cancer and personalized cancer care.
“As the only NCI* and NCCN* designated cancer center in the state of Washington, SCCA was established, in part, to help bring promising new treatments to patients faster,” said Nancy Davidson, MD, president and executive director of Seattle Cancer Care Alliance and a former ASCO president. “The presentations and publications with which our specialists are associated at ASCO demonstrate SCCA’s expertise in cancer diagnosis and treatment, including the clinical impact of COVID-19. They also represent some of the latest findings in clinical research that will enhance patient care today and into the future.”
More information about SCCA’s presentations and publications at ASCO is available at https://www.seattlecca.org/asco.
Oral Presentations
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis
Abstract: LBA1
SCCA author: Petros Grivas, MD, PhD, Clinical Director Genitourinary Medical Oncology
EMBARGO: Thursday, May 28, 5:00 p.m. ET
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19)
Abstract: LBA110
SCCA author: Petros Grivas, MD, PhD, Clinical Director Genitourinary Medical Oncology
EMBARGO: Thursday, May 28, 5:00 p.m. ET
SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA)
Abstract: 4504
SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab in combination with durvalumab for patients with advanced hepatocellular carcinoma
Abstract: 4508
SCCA author: William P. Harris, MD
IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC)
Abstract: 5000
SCCA author: Petros Grivas, MD, PhD, Clinical Director Genitourinary Medical Oncology
FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)
Abstract: 5007
SCCA author: Scott Tykodi, MD, PhD
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC)
Abstract: 500
SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416)
Abstract: 1001
SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology
TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)
Abstract: 1002
SCCA Author: Shaveta Vinayak, MD, MS
Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)
Abstract: 5007
SCCA Author: Scott Tykodi, MD
Poster Presentations
Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial
Abstract: 4618
SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology
Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced stage colorectal cancer (CRC-MRD Consortia)
Abstract: 4108
SCCA author: Stacey Cohen, MD
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)
Abstract: TPS4671
SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic
CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer
Abstract: 4018
SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic
Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD
Abstract: 7010
SCCA author: Veena Shankaran, MD, MS
A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01)
Abstract: 4582
SCCA author: David Zhen, MD
Cost implications of clinical trial (CT) participation in metastatic non-small cell lung cancer (NSCLC)
Abstract: 7084
SCCA authors: Keith Eaton, MD, PhD, Service Medical Director, Bernardo Goulart, MD, and Renato Martins, MD, MPH, Clinical Director, Thoracic, Head and Neck Oncology
Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients at the Puget Sound VA Prostate Oncology Clinic
Abstract: 1578
SCCA authors: Heather Cheng, MD, PhD, Director, Prostate Cancer Genetics Clinic, and Robert Montgomery, MD
Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427
Abstract: 5024
SCCA author: Scott Tykodi, MD, PhD
Title: Relation between measurable residual disease and morphologic relapse in AML
Abstract: 7535
SCCA author: Lauren Shih, MD
A phase I dose-escalation trial of alpha-tocopheryloxyacetic acid and concurrent trastuzumab in patients with treatment refractory HER2+ metastatic breast cancer
Abstract: TPS1103
SCCA Author: William Gwin, MD
Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105)
Abstract: 12019
SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology
Risk of cardiovascular disease in women with and without a history of breast cancer: The Pathways Heart Study
Abstract: 12016
SCCA Author: Heather Greenlee, ND, PhD, Director, Integrative Medicine Program
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)
Abstract: 1043
SCCA Author: Jennifer Specht, MD
A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer
Abstract: TPS 1104
SCCA Author: Jennifer Specht, MD
Prospective study of an AI enabled online intervention to increase delivery of guideline compliant cancer care on the ground
Abstract: 2011
SCCA Author: Benjamin Anderson, MD
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)
Abstract: 4671
SCCA Author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A
Abstract: 5069
SCCA Author: Scott Tykodi, MD
Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
Abstract: 1070
SCCA Author: Hannah Linden, MD
Gender differences in faculty rank and subspecialty choice in academic medical oncology
Abstract: 11013
SCCA Author: Nancy Davidson, MD, President and Executive Director
A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma
Abstract: 11517
SCCA Author: Michael Wagner, MD
PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.
Abstract: 9003
SCCA Author: Bernardo Goulart, MD
Publication Only
Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Abstract: e16050
SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology
Treatment patterns in pancreatic cancer: Differences between expert and community practitioners
Abstract: e19207
SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology
Phase I, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic or biliary cancers
Abstract: e16771
SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic
ER, PR, and HER2 expression in Ugandan breast cancer patients: An evaluation of in-country RT-PCR compared to IHC
Abstract: E19009
SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology
Patient-centered pathology reports for breast cancer care: Interim results of a randomized pilot study
Abstract: e19157
SCCA Author: Sara Javid, MD, Director, Breast Health Clinic
More information about SCCA’s research at ASCO20 Virtual Scientific Program can be found here: https://www.seattlecca.org/asco
About Seattle Cancer Care Alliance
Seattle Cancer Care Alliance (SCCA) brings together the leading research teams and cancer specialists from Fred Hutch, Seattle Children’s, and UW Medicine — one extraordinary group whose sole purpose is the pursuit of better, longer, richer lives for our patients. Based in Seattle’s South Lake Union neighborhood, SCCA has eight clinical care sites, including a medical oncology clinic at EvergreenHealth in Kirkland, Washington; medical and radiation oncology clinics at UW Medicine/Northwest Hospital & Medical Center in Seattle, Washington, medical and radiation oncology services at SCCA Peninsula and medical oncology services at SCCA Issaquah, as well as Network affiliations with hospitals in five states. For more information about SCCA, visit seattlecca.org.
*NCI – National Cancer Institute
*NCCN — National Comprehensive Cancer Network
Contacts
Karina San Juan-Guyton, ksanjuangu@seattlecca.org or (206) 606-1926
Heather Platisha, hplatisha@seattlecca.org or (415) 676-8030